Inmune Bio Files 8-K on Operations and Financials

TL;DR

Inmune Bio dropped an 8-K on March 28th covering financials and operations.

AI Summary

On March 28, 2024, Inmune Bio, Inc. filed an 8-K report detailing the results of operations and financial condition. The filing also includes information on other events and financial statements and exhibits. The company is incorporated in Nevada and its principal executive offices are located in Boca Raton, Florida.

Why It Matters

This 8-K filing provides crucial updates on Inmune Bio's financial health and operational status, which are important for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As an 8-K filing, it primarily contains factual disclosures about the company's operations and financial condition, which is generally considered medium risk as it doesn't inherently signal positive or negative news but requires investor analysis.

Key Players & Entities

• Inmune Bio, Inc. (company) — Registrant
• March 28, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• Boca Raton, Florida (location) — Principal Executive Offices
• 001-38793 (identifier) — Commission File Number

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share INMB The NASDAQ Stock Mar

Filing Documents

• ea0202918-8k_inmune.htm (8-K) — 28KB
• ea020291801ex99-1_inmune.htm (EX-99.1) — 86KB
• ex99-1_001.jpg (GRAPHIC) — 2KB
• 0001213900-24-027960.txt ( ) — 300KB
• inmb-20240328.xsd (EX-101.SCH) — 3KB
• inmb-20240328_lab.xml (EX-101.LAB) — 33KB
• inmb-20240328_pre.xml (EX-101.PRE) — 22KB
• ea0202918-8k_inmune_htm.xml (XML) — 4KB

02 Results

Item 2.02 Results of Operations and Financial Condition. On March 28, 2024, INmune Bio Inc. (the "Company") issued a press release announcing the Company's financial results for the year ended December 31, 2023 and providing a business update. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Current Report, including the exhibits hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document filed by the Company with the Securities and Exchange Commission, whether made before or after the date of this report, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. The information set forth under "Item 2.02 Results of Operations and Financial Condition" of this Current Report on Form 8-K is incorporated into this

01 by reference

Item 8.01 by reference.

01 Financial statements and Exhibits

Item 9.01 Financial statements and Exhibits (d) Exhibits. 99.1 Press Release for financial results and business update 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: March 29, 2024 By: /s/ David Moss David Moss Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR